150 related articles for article (PubMed ID: 30668525)
21. Identification of Driving ALK Fusion Genes and Genomic Landscape of Medullary Thyroid Cancer.
Ji JH; Oh YL; Hong M; Yun JW; Lee HW; Kim D; Ji Y; Kim DH; Park WY; Shin HT; Kim KM; Ahn MJ; Park K; Sun JM
PLoS Genet; 2015 Aug; 11(8):e1005467. PubMed ID: 26295973
[TBL] [Abstract][Full Text] [Related]
22. The genomic and transcriptomic landscape of anaplastic thyroid cancer: implications for therapy.
Kasaian K; Wiseman SM; Walker BA; Schein JE; Zhao Y; Hirst M; Moore RA; Mungall AJ; Marra MA; Jones SJ
BMC Cancer; 2015 Dec; 15():984. PubMed ID: 26680454
[TBL] [Abstract][Full Text] [Related]
23. Integrating Molecular Testing in the Diagnosis and Management of Children with Thyroid Lesions.
Ballester LY; Sarabia SF; Sayeed H; Patel N; Baalwa J; Athanassaki I; Hernandez JA; Fang E; Quintanilla NM; Roy A; López-Terrada DH
Pediatr Dev Pathol; 2016; 19(2):94-100. PubMed ID: 26366474
[TBL] [Abstract][Full Text] [Related]
24. Morphologic features of carcinomas with recurrent gene fusions.
Qi M; Li Y; Liu J; Yang X; Wang L; Zhou Z; Han B
Adv Anat Pathol; 2012 Nov; 19(6):417-24. PubMed ID: 23060067
[TBL] [Abstract][Full Text] [Related]
25. RET gene rearrangements (RET/PTC1 and RET/PTC3) in papillary thyroid carcinomas from an iodine-rich country (Japan).
Nakazawa T; Kondo T; Kobayashi Y; Takamura N; Murata S; Kameyama K; Muramatsu A; Ito K; Kobayashi M; Katoh R
Cancer; 2005 Sep; 104(5):943-51. PubMed ID: 16015630
[TBL] [Abstract][Full Text] [Related]
26. Prognostic factors in patients with Hürthle cell neoplasms of the thyroid.
Lopez-Penabad L; Chiu AC; Hoff AO; Schultz P; Gaztambide S; Ordoñez NG; Sherman SI
Cancer; 2003 Mar; 97(5):1186-94. PubMed ID: 12599224
[TBL] [Abstract][Full Text] [Related]
27. Activation of the RAS/RAF/ERK signaling pathway contributes to resistance to sunitinib in thyroid carcinoma cell lines.
Piscazzi A; Costantino E; Maddalena F; Natalicchio MI; Gerardi AM; Antonetti R; Cignarelli M; Landriscina M
J Clin Endocrinol Metab; 2012 Jun; 97(6):E898-906. PubMed ID: 22442268
[TBL] [Abstract][Full Text] [Related]
28. Molecular analysis of the RET and NTRK1 gene rearrangements in papillary thyroid carcinoma in the Polish population.
Brzeziańska E; Karbownik M; Migdalska-Sek M; Pastuszak-Lewandoska D; Włoch J; Lewiński A
Mutat Res; 2006 Jul; 599(1-2):26-35. PubMed ID: 16483615
[TBL] [Abstract][Full Text] [Related]
29. Targeted next generation sequencing identifies somatic mutations and gene fusions in papillary thyroid carcinoma.
Lu Z; Zhang Y; Feng D; Sheng J; Yang W; Liu B
Oncotarget; 2017 Jul; 8(28):45784-45792. PubMed ID: 28507274
[TBL] [Abstract][Full Text] [Related]
30. Phase 2 study evaluating the combination of sorafenib and temsirolimus in the treatment of radioactive iodine-refractory thyroid cancer.
Sherman EJ; Dunn LA; Ho AL; Baxi SS; Ghossein RA; Fury MG; Haque S; Sima CS; Cullen G; Fagin JA; Pfister DG
Cancer; 2017 Nov; 123(21):4114-4121. PubMed ID: 28662274
[TBL] [Abstract][Full Text] [Related]
31. High prevalence of BRAF gene mutation in papillary thyroid carcinomas and thyroid tumor cell lines.
Xu X; Quiros RM; Gattuso P; Ain KB; Prinz RA
Cancer Res; 2003 Aug; 63(15):4561-7. PubMed ID: 12907632
[TBL] [Abstract][Full Text] [Related]
32. A Case of Primary Mammary Analog Secretory Carcinoma (MASC) of the Thyroid Masquerading as Papillary Thyroid Carcinoma: Potentially More than a One Off.
Reynolds S; Shaheen M; Olson G; Barry M; Wu J; Bocklage T
Head Neck Pathol; 2016 Sep; 10(3):405-13. PubMed ID: 27075025
[TBL] [Abstract][Full Text] [Related]
33. Gene Fusions in Thyroid Cancer.
Yakushina VD; Lerner LV; Lavrov AV
Thyroid; 2018 Feb; 28(2):158-167. PubMed ID: 29281951
[TBL] [Abstract][Full Text] [Related]
34. Differentiated thyroid cancer: focus on emerging treatments for radioactive iodine-refractory patients.
Gruber JJ; Colevas AD
Oncologist; 2015 Feb; 20(2):113-26. PubMed ID: 25616432
[TBL] [Abstract][Full Text] [Related]
35. Clinical relevance of gene mutations and rearrangements in advanced differentiated thyroid cancer.
Nannini M; Repaci A; Nigro MC; Colapinto A; Vicennati V; Maloberti T; Gruppioni E; Altimari A; Solaroli E; Lodi Rizzini E; Monari F; De Leo A; Damiani S; Pagotto U; Pantaleo MA; de Biase D; Tallini G
ESMO Open; 2023 Dec; 8(6):102039. PubMed ID: 37879236
[TBL] [Abstract][Full Text] [Related]
36. Noninferior response in BRAF(V600E) mutant nonmetastatic papillary thyroid carcinoma to radioiodine therapy.
Li J; Liang J; Zhao T; Lin Y
Eur J Nucl Med Mol Imaging; 2016 Jun; 43(6):1034-9. PubMed ID: 26780618
[TBL] [Abstract][Full Text] [Related]
37. Genetic Alterations and Their Clinical Implications in High-Recurrence Risk Papillary Thyroid Cancer.
Lee MY; Ku BM; Kim HS; Lee JY; Lim SH; Sun JM; Lee SH; Park K; Oh YL; Hong M; Jeong HS; Son YI; Baek CH; Ahn MJ
Cancer Res Treat; 2017 Oct; 49(4):906-914. PubMed ID: 28052655
[TBL] [Abstract][Full Text] [Related]
38. Foundation One Genomic Interrogation of Thyroid Cancers in Patients With Metastatic Disease Requiring Systemic Therapy.
Iñiguez-Ariza NM; Jasim S; Ryder MM; Chintakuntlawar AV; Morris JC; Hilger CR; Menefee ME; Smallridge RC; Karlin NJ; Alcaino C; Bible KC
J Clin Endocrinol Metab; 2020 Jul; 105(7):e2346-57. PubMed ID: 32421817
[TBL] [Abstract][Full Text] [Related]
39. Comprehensive survey of HRAS, KRAS, and NRAS mutations in proliferative thyroid lesions from an ethnically diverse population.
Schulten HJ; Salama S; Al-Ahmadi A; Al-Mansouri Z; Mirza Z; Al-Ghamdi K; Al-Hamour OA; Huwait E; Gari M; Al-Qahtani MH; Al-Maghrabi J
Anticancer Res; 2013 Nov; 33(11):4779-84. PubMed ID: 24222113
[TBL] [Abstract][Full Text] [Related]
40. Molecular Pathology of Anaplastic Thyroid Carcinomas: A Retrospective Study of 144 Cases.
Bonhomme B; Godbert Y; Perot G; Al Ghuzlan A; Bardet S; Belleannée G; Crinière L; Do Cao C; Fouilloux G; Guyetant S; Kelly A; Leboulleux S; Buffet C; Leteurtre E; Michels JJ; Tissier F; Toubert ME; Wassef M; Pinard C; Hostein I; Soubeyran I
Thyroid; 2017 May; 27(5):682-692. PubMed ID: 28351340
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
